BEVACIZUMAB AS 4TH LINE TREATMENT IN METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Cannella, Lucia [1 ]
Carlomagno, Chiara [1 ]
De Stefano, Alfonso [1 ]
Alfieri, Salvatore [1 ]
Colantuoni, Maria [1 ]
Cella, Chiara [1 ]
De Placido, Sabino [1 ]
机构：
[1] Univ Federico II, Dept Endocrinol & Mol & Clin Oncol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [31] Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK
    Barnett, David
    Stevens, Andrew
    Longson, Carole
    LANCET ONCOLOGY, 2006, 7 (10): : 807 - 808
  • [32] COST ANALYSIS OF METASTATIC COLORECTAL CANCER TREATMENT WITH BEVACIZUMAB AND CETUXIMAB
    Maria Vieitez, Jose
    Oyaguez, Itziar
    Angel Casado, Miguel
    ANNALS OF ONCOLOGY, 2011, 22 : v84 - v84
  • [33] Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer
    Varol, Umut
    Yildiz, Ibrahim
    Salman, Tarik
    Karabulut, Bulent
    Uslu, Ruchan
    TUMORI JOURNAL, 2014, 100 (04): : 370 - 376
  • [34] Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer
    Cao, Dan
    Guo, Chun-hong
    Liu, Jie-wei
    Yang, Xi
    Li, Qiu
    TUMORI JOURNAL, 2015, 101 (01): : 46 - 51
  • [35] Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer
    Varol, Umut
    Oktay, Esin
    Yildirim, Mustafa
    Surmeli, Zeki Gokhan
    Dirican, Ahmet
    Meydan, Nezih
    Karaca, Burcak
    Karabulut, Bulent
    Uslu, Ruchan
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 166 - 170
  • [36] Treatment of Cancer (4th edn)
    Vanessa Gill
    British Journal of Cancer, 2003, 88 (10) : 1659 - 1660
  • [37] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [38] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [39] The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) : 2487 - 2494
  • [40] Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
    Rossi, Luigi
    Veltri, Enzo
    Zullo, Angelo
    Zoratto, Federica
    Colonna, Maria
    Longo, Flavia
    Mottolese, Marcella
    Giannarelli, Diana
    Ruco, Luigi
    Marchetti, Paolo
    Romiti, Adriana
    Barucca, Viola
    Giannini, Giuseppe
    Bianchi, Loredana
    Tomao, Silverio
    ONCOTARGETS AND THERAPY, 2013, 6 : 1761 - 1769
12345